APA (7th ed.) Citation

PG, M., LC, C., S, A., AW, N., DM, L., SM, F., . . . AO, T. (2010). Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: An alternative treatment for C2 deficiency diseases. BMC immunology, 11, 43. https://doi.org/10.1186/1471-2172-11-43

Chicago Style (17th ed.) Citation

PG, Martini, et al. "Recombinant Human Complement Component C2 Produced in a Human Cell Line Restores the Classical Complement Pathway Activity In-vitro: An Alternative Treatment for C2 Deficiency Diseases." BMC Immunology 11 (2010): 43. https://doi.org/10.1186/1471-2172-11-43.

MLA (9th ed.) Citation

PG, Martini, et al. "Recombinant Human Complement Component C2 Produced in a Human Cell Line Restores the Classical Complement Pathway Activity In-vitro: An Alternative Treatment for C2 Deficiency Diseases." BMC Immunology, vol. 11, 2010, p. 43, https://doi.org/10.1186/1471-2172-11-43.